Case-Based Roundtable Meetings Spotlight: May 2022

Lee Discusses Current Landscape in Management of Clear Cell RCC

June 05, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the use of approved combination regimens including tyrosine kinase inhibitors and immune checkpoint inhibitors for a patient with clear cell renal cell carcinoma.

Roundtable Discussion: Budde Focuses on the Factors Affecting Treatment Decisions in B-cell Lymphoma

June 04, 2022

Clinical Articles

During a Targeted Oncology case-based event, Elizabeth Budde, MD, PhD, discussed with participants the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was not eligible for stem cell transplant and declined chimeric antigen receptor T-cell therapy.

Socinski Reviews Targeted Treatment in NSCLC and ES-SCLC

June 03, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Mark A. Socinski, MD, discussed the results of clinical trials supporting the use of targeted agents in patients with late-stage lung cancers.

Roundtable Discussion: Graff and Participants Debate Treatment Choices in TNBC

June 01, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Stephanie L. Graff, MD, discussed the case of a patient with triple-negative breast cancer who progressed following adjuvant chemotherapy and frontline carboplatin treatment.

Roundtable Discussion: Jonasch Discusses the Management of Clear Cell RCC

May 28, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event in Texas, Eric Jonasch, MD, moderated a discussion around the management of clear cell renal cell carcinoma in a 59-year-old African American female patient.

Roundtable Discussion: Ademuyiwa Covers the Benefits and Challenges of Using Sacituzumab in Certain Populations of TNBC

May 27, 2022

Clinical Articles

During a case-based roundtable event, Foluso Olabisi Ademuyiwa, MD, MPH, MSCI and a group of peers discussed the benefits and challenges with using sacituzumab govitevan to treat a 48-year-old patients with triple-negative breast cancer.